Eisai
4523.T
#851
Rank
$20.03 B
Marketcap
$69.87
Share price
3.16%
Change (1 day)
73.72%
Change (1 year)
Eisai is a Japanese pharmaceutical company that is engaged in the R&D of drugs for the treatment of dementia and Alzheimer.

P/E ratio for Eisai (4523.T)

P/E ratio as of June 2023 (TTM): 12.2

According to Eisai's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 12.1935. At the end of 2022 the company had a P/E ratio of 34.7.

P/E ratio history for Eisai from 2009 to 2022

PE ratio at the end of each year

Year P/E ratio Change
202234.7-31.84%
202150.9176.41%
202018.4-34.77%
201928.3-24.51%
201837.4-11.78%
201742.418.3%
201635.9-38.22%
201558.070.38%
201434.142.31%
201323.949.41%
201216.027.64%
201112.6-47.42%
201023.934.75%
200917.7-131.35%
2008-56.5-338.2%
200723.72.6%
200623.122.73%
200518.815.83%
200416.33%
200315.8-37.15%
200225.1-36.64%
200139.7

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.